Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...

The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinanci ...

New board reflects company's added focus on oncology & autoimmune diseases; SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the ... HCC remains one of the commonest malignant diseases in the world but it has ...

Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...